Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Efficacy of INTOFINE-JOINT SUPPORT DIETARY SUPPLEMENT on Bone and Joint Health

15 juin 2026 mis à jour par: Hong Kong Junhuo Biotechnology Co., Limited

Efficacy and Safety Evaluation of INTOFINE-JOINT SUPPORT DIETARY SUPPLEMENT in Improving Knee Joint Function

The goal of this clinical trial is to evaluate whether INTOFINE-JOINT SUPPORT DIETARY SUPPLEMENT improves joint health in adults aged 40-60 years with mild symptomatic knee osteoarthritis (defined by WOMAC total score 20-32 and knee pain VAS score 2-4). It will also assess the safety of the test product.

The main questions it aims to answer are:

Does the test product relieve knee pain, stiffness and physical activity difficulty measured by the WOMAC Osteoarthritis Index? Does the test product reduce pain intensity evaluated by the VAS Pain Scale? Can the test product improve 6-minute walking distance, sit-to-stand ability, stair-climbing performance and the range of motion of the hip and knee joints? What adverse reactions or safety issues do participants have when taking the test product? This is a single-arm, self-controlled clinical trial. Researchers will compare the test results of participants before and after taking the product to verify its efficacy in improving joint function.

Participants will:

Take 2 capsules of the test product once daily, 1 hour after meals, for 60 consecutive days Complete subjective efficacy evaluations, scale assessments and joint function tests at D3, D5, D14, D30, D40 and D60 Undergo safety follow-up tests of blood glucose, liver function and renal function at D56 Report joint symptoms and provide satisfaction feedback during the trial period

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Réel)

33

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Chine
    • Guangdong
      • Guangzhou, Guangdong, Chine
        • Guangzhou Jinyu Health Examination Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Male and female volunteers aged 40-60 years with symptoms of mild knee joint dysfunction; total WOMAC scores ranging from 20 to 32 points, and VAS scores within 2-4 points.
  • In good general health, free from hypertension, diabetes mellitus, systemic diseases and other chronic underlying diseases.
  • No documented history of allergy to any ingredients of the test product.
  • Able to strictly follow the requirements and time schedule of the study protocol, and voluntarily sign the informed consent form.

Exclusion Criteria:

  • Subjects aged less than 40 years or more than 60 years.
  • Those suffering from severe primary diseases involving cardiovascular and cerebrovascular systems, liver, kidney, hematopoietic system and other vital organs.
  • Individuals who have received knee joint surgery within one year.
  • Subjects who underwent intra-articular injection within the past 3 months.
  • Those who have taken anti-arthritic medications (including analgesic drugs) within the preceding one month.
  • Patients clinically diagnosed with gout or hyperuricemia.
  • Females who are pregnant, breastfeeding, or planning to conceive within the next two months.
  • Subjects with severe hepatic or renal insufficiency, hemorrhagic diseases, or those taking anticoagulant drugs.
  • Participants currently or within the last one month enrolled in other clinical trials related to the tested joint site.
  • The final decision on subject enrollment shall be made by the investigators.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: People aged 40-60 with mild knee osteoarthritis
Take INTOFINE-JOINT SUPPORT DIETARY SUPPLEMENT, one capsule at a time, twice a day, during or after meals,
Complément alimentaire: INTOFINE-JOINT SUPPORT DIETARY SUPPLEMENT
Take one pill at a time, twice a day, with meals or after meals

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in WOMAC Osteoarthritis Index Total Score
Délai: From baseline (Day 0) to the end of the 60-day intervention period, subjects completed efficacy evaluations at six predefined time points: Day3, Day 5, Day 14, Day 30, Day 40, and Day 60.
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a 24-item questionnaire that measures knee pain, stiffness, and difficulty with daily activities. Scores range from 0 (no symptoms) to 96 (severe symptoms). The primary endpoint is the change in total score from baseline to the end of the study, to assess overall improvement in knee function.
From baseline (Day 0) to the end of the 60-day intervention period, subjects completed efficacy evaluations at six predefined time points: Day3, Day 5, Day 14, Day 30, Day 40, and Day 60.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in Knee Pain Intensity (VAS Score)
Délai: Baseline (day 0), day28 and day 56
Knee pain is measured using a 10-point Visual Analog Scale (VAS), where 0 = no pain and 10 = worst possible pain. Participants rate their pain at rest and during daily activities (e.g., walking, climbing stairs). Changes in these scores from baseline are tracked over the intervention period.
Baseline (day 0), day28 and day 56
6-minute walk test (distance walked in 6 minutes)
Délai: Baseline (day 0), day28 and day 56

The test is conducted in a 20-30 meter flat corridor, with the ambient temperature maintained at 20-25℃ and relative humidity at 40%-60%. Upon instruction, the subject walks continuously for 6 minutes at the maximum tolerable speed. The tester gives a time reminder every minute. If the subject feels significant discomfort, they may rest or terminate the test at any time, and relevant information shall be documented. Once the timing ends, the final position of the subject is recorded, and the total walking distance is calculated.

Reporting method:Change from baseline to Day 28 and Day 56, presented as the mean distance, mean change from baseline, and percentage improvement at each time point.
Baseline (day 0), day28 and day 56
Participant Global Assessment of Knee Symptom Improvement
Délai: From baseline (Day 0) to the end of the 60-day intervention period, subjects completed efficacy evaluations at six predefined time points: Day 3, Day 5, Day 14, Day 30, Day 40, and Day 60.
At the end of the study, participants rate their overall knee symptom improvement using a 5-point scale (1 = much worse, 5 = much better). This self-reported measure captures how participants perceive the effect of the intervention on their daily lives.
From baseline (Day 0) to the end of the 60-day intervention period, subjects completed efficacy evaluations at six predefined time points: Day 3, Day 5, Day 14, Day 30, Day 40, and Day 60.
Sit-to-stand test
Délai: Baseline(day 0), day28 and day 56

1.Test Requirements: Subjects complete 3 consecutive stand-sit movements at a uniform speed without external assistance from handrails, walls or other supports.

2.Evaluation Criteria：

  1. Excellent: All 3 movements are standard with upright trunk, no body sway or knee pain, and no auxiliary support required.
  2. Good: All 3 movements are basically standard with occasional slight self-adjustable sway, no knee pain, and no auxiliary support required.
  3. Pass: Slight knee soreness or obvious body sway occurs during movements, or 1-2 movements require knee support by hands to complete.
  4. Fail: Unable to complete movements independently, requiring external assistance; or presenting with collapsing sitting posture and obvious lower limb weakness during standing up.

3.Reporting method: Change in sit-to-stand test score from baseline and percentage improvement at each time point.
Baseline(day 0), day28 and day 56
Stair-climbing test
Délai: Baseline (day 0), day 28 and day 56

Subjects complete a stair-climbing test on a 30-step staircase (16 cm per step). Performance is scored on a 4-point scale based on knee pain, stability, and functional ability to assess improvements in joint function and mobility.

Reporting method:Change in sit-to-stand test score from baseline to Day 56, presented as the mean change and percentage improvement from baseline.
Baseline (day 0), day 28 and day 56
Joint range of motion
Délai: Baseline (day 0), day28 and day 56
Test items: hip external rotation, hip internal rotation, knee flexion and extension Reporting method: Change in hip external rotation, hip internal rotation, knee flexion and extension range of motion (degrees) from baseline to test day, presented as the mean change and percentage improvement from baseline.
Baseline (day 0), day28 and day 56
Changes in liver function parameters
Délai: Baseline (day 0), Day 56
Test items:Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-Glutamyl Transferase（GGT） Reporting method: Changes in each parameter at baseline and Day 56, as well as the proportion of subjects with values exceeding the upper limit of normal range
Baseline (day 0), Day 56
Changes in renal function parameters
Délai: Baseline (day 0), Day 56
Test items: Urea (UREA), Creatinine (Cr), Uric Acid (UA) Reporting method: Changes of each parameter at baseline and Day 56, and the proportion of subjects with values exceeding the upper limit of normal range.
Baseline (day 0), Day 56

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Hong Kong Junhuo Biotechnology Co., Limited

Collaborateurs

Guangzhou King Test Technology Co., Ltd.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

15 janvier 2026

Achèvement primaire (Réel)

12 mars 2026

Achèvement de l'étude (Réel)

12 mars 2026

Dates d'inscription aux études

Première soumission

2 juin 2026

Première soumission répondant aux critères de contrôle qualité

15 juin 2026

Première publication (Réel)

22 juin 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

22 juin 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

15 juin 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • GZ251212069

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner